ACRV Earnings Date: Nov 12, 2026 (Estimated) — Acrivon Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
Updated
When is ACRV's next earnings date?
Acrivon Therapeutics, Inc. Common Stock (ACRV) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.45 on revenue of $504,333.
How did ACRV do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Acrivon Therapeutics, Inc. Common Stock posted EPS of -$0.43 versus the -$0.50 estimate, a beat of 14.0%. Revenue was $0 against a $386,333 estimate. The stock's 1-day post-earnings move was +7.6%.
How much does ACRV stock move after earnings?
ACRV beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.8% (up or down) in the day after earnings.
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.50 | -0.43 | +14.00% | $0 | ✅ Beat | +7.56% | +38.95% | +16.28% |
| 2026-05-13 | Q1 2026 | -0.51 | -0.49 | +3.92% | $0 | ✅ Beat | +0.00% | -8.33% | -22.92% |
| 2026-03-19 | Q4 2025 | -0.47 | -0.49 | -4.26% | $0 | ❌ Miss | +3.66% | -7.32% | +8.54% |
| 2025-11-13 | Q3 2025 | -0.58 | -0.47 | +18.97% | $0 | ✅ Beat | +8.21% | +9.18% | +24.15% |
| 2025-08-13 | Q2 2025 | -0.58 | -0.55 | +5.17% | $0 | ✅ Beat | +6.11% | -0.76% | +16.03% |
| 2025-03-27 | Q4 2024 | -0.65 | -0.60 | +7.69% | $0 | ✅ Beat | -11.11% | -34.92% | -38.49% |
| 2024-11-13 | Q3 2024 | -0.58 | -0.59 | -1.72% | $0 | ❌ Miss | -5.48% | -23.96% | -16.33% |
| 2024-08-13 | Q2 2024 | -0.60 | -0.52 | +13.33% | $0 | ✅ Beat | -4.48% | +9.75% | +25.16% |
Showing last 8 quarters.